1996 (v1)
Publication
No description
Uploaded on: May 13, 2023
A
A
Last name: ARDIZZONI
First name: Andrea
No description
The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the...